Significance, 121 words Introduction, 690 words
JPET #244939
Introduction JPET #244939 8 consistent stage 5 seizures. This procedure has been used extensively as a model of compressed epileptogenesis as an alternative paradigm to the conventional kindling models (Sankar et al., 2010; Reddy and Mohan, 2011) .
Motor Toxicity Test. Sodium butyrate and other test drugs were evaluated for motor toxicity by using a modification of the horizontal screen test as described previously (Reddy and Jian, 2010) . Mice were placed on a horizontally oriented grid (consisting of parallel 1.5-mm diameter rods situated 1 cm apart), and the grid was inverted. Mice failing to remain on the screen for 60 seconds were considered failures due to excessive sedation or motor ataxia.
Brain Histological Timm Staining. Timm staining of mossy fiber sprouting is a standard histological index of epileptogenesis. Timm staining was conducted as described previously (Cavazos et al., 1991; Rao at al., 2006) .
Mice were deeply anesthetized with ketamine/xylazine mix and transcardially perfused with 75 mL 0.9% saline solution followed by 100 mL 1% sodium sulfide solution. Perfusion of 100 mL of 4% paraformaldehyde in 0.1 M phosphate buffer (7.4 pH) followed, and a final perfusion with 50 mL 1% sodium sulfide was carried out. The brain was dissected and postfixed in 4% paraformaldehyde overnight at 4˚C. Brains were then processed with phosphate buffer and sucrose treatment and cut in 20 μm transverse sections with a cryostat. Slices were then drymounted onto slides and allowed to dry overnight. Gum arabic, citrate buffer, hydroquinone, and silver lactate reagents were mixed mechanically on the day of staining. Mounted slides were uniformly soaked in the Timm stain in dark for 3.5 hours. Slides were then washed with distilled water and counter-stained with 0.1% cresyl violet, if desired. Slides were permanently fixed with DPX mountant (Sigma) and allowed to dry before imaging and analysis. Staining intensity for Timm histology was quantitatively measured by densitometric analysis.
Densitometry was completed in hippocampus regions of interest with Photoshop software. Mean density of grayscale staining was normalized to area and white background. Density scores were then non-parametrically graded using a linear scale.
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Test Drugs and Treatment Protocols. There are many HDAC inhibitors, such as vorinostat, trichostatin-A, valproic acid, and sodium butyrate (Younus and Reddy, 2017b) . Sodium butyrate was the focus of this study for its broad-spectrum HDAC inhibition (Ferrante et al., 2003; Deutsch et al. 2008; Takuma et al., 2014) . Valproic acid, a widely used antiepileptic drug, was not used because it is a limited-spectrum HDAC inhibitor and hence offers comparatively limited disease-modification of epileptogenesis (Silver et al., 1991; Gurvich et al., 2004; Takuma et al., 2014) . The overall experimental protocol for drug treatment and kindling stimulations is illustrated in Fig. 2 . In the first kindling development study (Protocol #1), sodium butyrate (600 mg/kg) was injected intraperitoneally twice daily (9 A.M. and 5 P.M.) to maintain chronic HDAC inhibition. The dose of butyrate used in this study has been shown previously to significantly inhibit multiple HDACs and reliably increase the acetylation of H3 and H4 histones in the brain and other tissues (Ferrante et al., 2003; Takuma et al., 2014) .
Sodium butyrate has been shown to effectively inhibit downstream H4 and H4 histone signaling in cells in vitro and after administration in animals (Davie, 2003; Minamiyama et al., 2004) . Our design consists of treated animals (n = 11) alongside an untreated control group (n = 10). Animals were stimulated daily in the morning and received their respective treatments daily until becoming fully kindled. Kindling, however, is a permanent phenomenon and an intense seizure can be elicited weeks or months after kindling development. Therefore, eight weeks after inducing stage 5 kindling, both groups of mice were tested for persistence of the kindling state by restimulation at the baseline ADT. Additionally, mice were also tested for retention through additional stimulations at 20 minute intervals, increasing current in 25 µA increments until the occurrence of stage 4 or 5 seizures. This protocol is henceforth referred to as "chronic treatment." In the second kindling development study (Protocol #2), sodium butyrate (600 mg/kg) was injected intraperitoneally twice daily (9 A.M. and 5 P.M.) for exactly 14 days, and animals were stimulated daily even after the end of drug treatment until they became fully kindled. These animals (n = 8) were treated alongside animals (n = 9) receiving the synthetic neurosteroid ganaxolone (0.5 or 1.0 mg/kg) 15 minutes prior to stimulation for 14 days, as well as a combination group (n = 9) receiving butyrate twice daily and ganaxolone 15 minutes prior to stimulation. Ganaxolone (GX, is an allosteric modulator of GABA-A receptor with antiseizure properties (Reddy and Rogawski, 2010). This protocol is henceforth referred to as "subchronic treatment." The final kindling study format (Protocol #3), involves two groups of animals stimulated daily without any drug treatment until achieving complete kindling. To test the retroactive effect of epigenetic treatment on epilepsy-susceptible mice, sodium butyrate (600 mg/kg, i.p.) was injected twice daily in the experimental group (n=17) for two weeks, during which time no stimulations were conducted. A control group (n=12) received no treatment during this time. At the end of the treatment period, ADTs were redetermined for all animals and all mice were rekindled until they exhibited consistent stage 5 seizures. In another test, as a measure of the drugs' acute seizure suppression, butyrate and/or ganaxolone were also administered as one-time pretreatments to previously kindled mice. In parallel studies, we tested the effect of the synthetic neurosteroid ganaxolone on kindling progression. GX is an effective antiseizure agent in the kindling model (Reddy and Rogawski 2010) . Age-matched male mice (n = 7-10) were given sodium butyrate (300 or 600 mg/kg, i.p.) approximately 2 hours before stimulation, GX (0.5 or 1.0 mg/kg, s.c.) 15 minutes before stimulation, or both butyrate (600 mg/kg) and GX (0.5 mg/kg) before stimulation.
Data Analysis. Group data are expressed as the mean ± standard error of the mean (SEM). Differences in kindling seizure stages between groups were compared with the nonparametric Kruskal-Wallis test followed by the Mann-Whitney U-test. Comparison of means of the AD duration between groups was made with a one-way analysis of variance, followed by an unpaired two-tailed Student's t-test. Comparison of the percent animals exhibiting seizures and percent difference in seizure duration in various groups was made by Wilcoxon signed ranks test. In all statistical tests, the criterion for statistical significance was p < 0.05.
Results
Sodium Butyrate Inhibits HDAC Activity in the Brain. To determine the ability of sodium butyrate to inhibit HDAC activity, we performed HDAC activity assay in hippocampus and cortex samples from untreated control and butyrate-treated (600 mg/kg, i.p.) mice. HDAC activity assay was carried out by the Fluor-de-Lys HDAC activity assay kit, as described previously (Nian et al., 2009; Rajendran et al., 2011 HDAC activity in the hippocampus and cortex of mice treated with sodium butyrate was significantly (20-40%, p<0.05) reduced compared to that of control mice. Hippocampal HDAC activity in the butyrate group (1.0 ± 0.02 HDAC % control after normalization per µg protein) was significantly lower than in the control group (1.2 ± 0.06). Similarly, sodium butyrate significantly reduced HDAC activity in the cortex (1.1 ± 0.01 HDAC % control after normalization per µg protein) compared to the control group (1.5 ± 0.16). These results confirm a significant inhibition of HDAC activity in mice following sodium butyrate treatment, as consistent with earlier reports (Ferrante et al., 2003; Takuma et al., 2014) .
Acute HDAC Inhibition Produces Little Change in Seizure Expression in Fully-kindled Mice. To determine the acute effect of HDAC inhibition by sodium butyrate on kindled seizures, we tested butyrate in a dose-dependent fashion in fully-kindled mice expressing stage 5 (generalized) seizures. The acute effect of sodium butyrate is shown in Fig. 3 . Sodium butyrate pretreatment 1-h before stimulation in fully-kindled animals provided little or no seizure protection, as evident from the lack of seizure suppression by either dose of butyrate (Fig. 3A) . Butyrate also did not significantly affect the mean afterdischarge (AD) duration (Fig. 3B) . To determine the comparative and combination efficacy, we also tested a neurosteroid antiseizure agent ganaxolone (Reddy and Rogawski, 2010) . Our results show that while neither a low dose of ganaxolone (0.5 mg/kg) or a combination treatment of butyrate and ganaxolone provided acute protection, a high dose of ganaxolone (1.0 mg/kg) displayed modest seizure protection (Fig. 3D) . None of these treatments, however, significantly influenced AD duration (Fig. 3E ). An important criterion to take into consideration when determining dose selection, however, is the significant animal behavioral sedation resulting from high dosage, which is not as prevalent in the selected doses of butyrate or ganaxolone (Fig. 3CF) . In addition, we tested the effect of sodium butyrate on acute seizures at longer intervals between treatment and stimulation. Similar seizure outcomes resulted even 4 h after treatment, as all animals exhibited stage 4/5 seizures (n = 9/group). These results indicate that acute treatment with butyrate has no effect on seizure expression and motor behavior. To determine the chronic effect of HDAC inhibition by sodium butyrate on kindled epileptogenesis progression, we administered butyrate twice daily to several animals, which were concurrently kindled with a control group (Fig. 2) . The development of kindled seizures in control mice and mice treated daily with sodium butyrate (600 mg/kg) is shown in Fig. 4 . There was no significant difference in mean AD threshold between the control and butyrate groups (Fig. 4B) . Sodium butyrate produced marked impairment in the development of kindling epileptogenesis, most evident in the significant suppression of seizures at corresponding stimulation sessions compared to the control (Fig. 4C) . Mean AD duration, however, was not significantly reduced (Fig. 4D ). Mice treated with butyrate also showed a drastically decreased rate of kindling, measured by the number of stimulations required to elicit three consecutive stage 5 (generalized) seizures, in comparison to the control group (Fig. 4E , Table 1 ). These results indicate the striking epileptogenesis-delaying effect of persistent HDAC inhibition by butyrate treatment.
Chronic HDAC Inhibition by Sodium Butyrate Impairs Lasting Retention of Limbic Epileptogenesis.
To examine the long-term antiepileptogenic inhibition of sodium butyrate, both groups of animals were restimulated at their baseline AD threshold eight weeks after the initial chronic kindling to determine the strength of epileptogenic retention (Fig. 5 ). While the majority of control animals still displayed severe generalized seizures (stages 4 or 5), only a slight minority of animals treated with butyrate in the initial study showed such seizures, demonstrating butyrate's prolonged disease-modifying effect even without drug administration (Fig.   5A ). Furthermore, during AD threshold redeterminations (Fig. 5B ), butyrate-treated animals displayed significant seizure resistance compared to control animals at corresponding stimulation currents, and this butyrate group required 50 µA more current (a 33% increase) than the control group to achieve stage 5 seizures. Butyrate did not significantly affect the mean AD duration in this retention study (Fig. 5C ). These results indicate that HDAC inhibition by sodium butyrate carries a long-lasting antiepileptogenic or disease-modification effect.
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Subchronic HDAC Inhibition by Sodium Butyrate Inhibits the Development of Limbic
Epileptogenesis. To observe the effects of sodium butyrate treatment and discontinuation within the same kindling cycle, we administered sodium butyrate to various subgroups, alongside a control group, for two weeks, and then allowed kindling to continue without treatment (Fig. 2) . The development of kindled seizures in control mice and mice treated for 14 days with sodium butyrate (600 mg/kg) is shown in Fig. 6 . There was no significant difference in mean AD threshold between any of the four groups in the study (Fig. 6E) . During the fourteen days of injection, sodium butyrate strikingly inhibited the development of kindling epileptogenesis (Fig.7) , seen prominently in the significantly reduced seizure stages at corresponding stimulation sessions compared to the control ( Fig. 6A) . Butyrate, however, did not significantly affect the mean AD duration overall ( Table 1 ), which indicates a true antiepileptogenic effect. To determine whether inhibition of HDAC confers synergistic effects when used in combination with an antiseizure drug, we sought to study the effect of the synthetic neurosteroid ganaxolone alone or in combination with butyrate. Treatments of ganaxolone (0.5 mg/kg), as well as the combination treatment of ganaxolone (0.5 mg/kg) and butyrate (600 mg/kg), induced similar levels of epileptogenic retardation as compared to butyrate group alone (Fig. 4C) . Similarly, these treatments also did not significantly affect the mean AD duration (Fig. 6D) . Expectedly, the antiepileptogenic butyrate and/or ganaxolone treatments significantly retarded the development of kindled seizures compared to the control ( Fig.   6F ), indicating a modest synergistic protection offered by the antiseizure ganaxolone.
Acute HDAC Inhibition Fails to Affect Epileptogenic-like Response in Rapid Kindling Epileptogenesis.
To further elucidate the effective window of HDAC mechanisms in susceptibility to epileptogenesis (acute vs. chronic inhibition), we utilized the "rapid kindling" model of acute epileptogenesis, the process of epilepsy induction by stimulation every 30 min (acute), rather than the once-daily (chronic) stimulation implemented in the classic kindling model. Acute treatment with butyrate did not modify the rapid kindling progression, as evident by the essentially identical seizure stage and AD duration curves of control and butyrate groups (Fig. 8A,B,C,D) . A representative EEG discharge is shown in Fig. 8E . There was no significant difference in mean AD threshold between the control and butyrate groups (Fig. 8C) . Furthermore, butyrate did not significantly affect the rate of kindling compared to the control, indicating the inability of butyrate treatment for acute HDAC inhibition to inhibit rapid epileptogenic development (Fig. 8D) . These results are consistent with the evidently delayed effects of epigenetic interruption of epileptogenesis.
HDAC Inhibition Reverses Epileptogenic State in Fully-kindled Epileptic Animals.
To determine any disease-modification effects of HDAC inhibition in animals which have already developed advanced stages of epilepsy, we administered butyrate in previously fully-kindled animals with stage 5 (generalized) seizures for checking epileptogenic reversal or erasal of epileptic state. Animals were fully kindled without any injected treatment until they show consistent stage 5 seizures, followed by a two week period of butyrate treatment (600 mg/kg, i.p., twice daily) and hiatus from stimulation (Fig. 2) . On the sixth week, treatment was discontinued and individual AD threshold were redetermined. Animals were subsequently rekindled to full without treatment, identical in procedure to the initial kindling. Butyrate-treated mice displayed a significant reduction in seizure severity when tested the week following termination of butyrate therapy (Fig. 9A) . During rekindling, butyratetreated mice required significantly more stimulations to rekindle fully (Fig. 9A,C) . Furthermore, AD duration among treated mice progressively increased, while AD durations of control mice remained relatively constant across stimulations (Fig. 9B) . Thus, these results indicate that HDAC inhibition by butyrate treatment can promote significant unwiring or erasal of even prior chronic epileptogenic state ("curing epilepsy").
HDAC Inhibition Prevents Epileptogenic Mossy Fiber Axonal Sprouting in the Hippocampus.
To determine whether HDAC inhibition by sodium butyrate treatment is associated with morphological changes in neuronal circuits involved in epileptogenesis, we examined the extent of mossy fiber sprouting in hippocampus samples isolated from control and butyrate-treated animals. The pathological role of mossy fiber sprouting in temporal lobe epileptogenesis is controversial because inhibition of mossy fiber sprouting may not reflect an antiepileptogenic process (Heng et al., 2013) . Nevertheless, mossy fiber sprouting is the most commonly-used morphological marker of epileptogenesis in experimental models and it provides valuable information on the impact of therapeutic interventions on aberrant sprouting of granule cell axons in the dentate gyrus. A characteristic histological sign of TLE is the loss of hilar cells in the dentate gyrus and mossy fiber sprouting.
Mossy cells in the hippocampus are highly excitable. Mossy cells are bi-directionally connected through a positive feedback loop to granule cells, the principal cells of the dentate gyrus. This recurrent circuit is strategically placed between the entorhinal cortex and the CA3 region and thus potentially pro-convulsive and may promote epileptogenesis (Ratzliff et al., 2002) . We observed a significant increase in mossy fiber sprouting in control, fully-kindled animals (Fig. 10A) . Quantification of axonal sprouting within the dentate gyrus region by densitometry and staining intensity scoring revealed complete reversal of seizure-induced increase in mossy fiber sprouting in animals treated with butyrate ( Fig. 10BCDE) , suggesting possible disease-modification from HDAC inhibition. Butyrate when given in combination with ganaxolone also resulted in significant reduction in mossy fiber sprouting (Fig. 10AE) , indicating further disease-modifying potential of the antiseizure treatment with ganaxolone. showed further disease-modification of epileptogenesis. Collectively, these results indicate that the HDAC signaling pathway mediates the development and persistence of epileptogenesis in an experimental model of TLE.
DISCUSSION

Epigenetic HDACs Signaling in Epilepsy.
There is emerging evidence that epigenetic signaling plays a crucial role in the pathophysiology of epileptogenesis and chronic epilepsy (Qureshi and Mehler, 2010; Kobow and Blumcke, 2014; Younus and Reddy, 2017b) . The main epigenetic mechanisms include histone modifications, DNA methylation, and miRNA-based transcriptional control (Fig. 1) . The primary histone modification associated with epilepsy and other neural disorders is lysine acetylation at the histone tail (Kobow and Blumcke, 2014). Histone acetylation is catalyzed by histone acetyltransferases and histone deacetylation is carried out by histone deacetylases. As a result of these two opposing epigenetic modifications, chromatin is known to exist in sodium butyrate. It is likely that these effects of sodium butyrate are unrelated to HDAC inhibition. For example, sodium butyrate is a short chain fatty acid used as an energy source and directly stimulates NF-ΚB transcription (Borthakur et al., 2008) . However, this is highly unlikely given the significant mechanistic data on HDAC inhibition as assessed by HDAC activity in brain samples. Moreover, there is little evidence of NF-ΚB involvement in seizure susceptibility.
Subchronic and Chronic HDAC Inhibition Retards Epileptogenesis.
In the present study, sodium butyrate treatment inhibited HDAC activity but produced no acute antiseizure effect in epileptic animals.
Similarly, butyrate treatment was ineffective in reducing the development of rapid kindling. These outcomes were expected given the longer time necessary for the HDAC inhibitor to affect enough gene networks and synaptic processes to manifest in significant protection. During chronic treatment, butyrate significantly hindered the rate of kindling epileptogenesis without affecting afterdischarge progression. The extent of protection, however, was similar to that of antiseizure ganaxolone treatment given fifteen minutes before each stimulation. Although both treatments produced similar protective effects against epileptogenesis, sodium butyrate shows exceptionally longlasting protection (disease-modification), whereas ganaxolone only temporarily suppressed the seizure occurrence. To delineate the difference between the modes of action of HDAC inhibition, we also performed a subchronic study, wherein animals received butyrate for 2 weeks only, but continued to get stimulations until they reached the epileptogenic state. During the treatment window, both butyrate and ganaxolone provided significant hindrance of the kindling process. When treatment was discontinued, however, epileptogenic progression rapidly rose in ganaxolone-only groups, while all butyrate-treated groups saw chronic seizure protection even after treatment was discontinued. These results suggest that the induction and persistence of limbic epileptogenesis are markedly reduced by HDAC activity inhibition by butyrate. Focal electrographic AD is required for induction of epileptogenesis in the kindling model (Goddard et al., 1969; Albertson et al., 1984) . The delayed kindling development after HDAC inhibition is not due to differences in focal electrographic seizures because the duration of evoked AD was similar among control and butyrate groups during the early stimulation session. However, the progressive increase in duration of the AD activity with successive stimulations was significantly attenuated in the butyrate group. Since butyrate did not affect rapid kindling progression, the structural and functional circuits that are required to exhibit behavioral and electrographic seizures are not affected by acute HDAC inhibition. Thus, the complex plasticity that is required for transforming a normal brain to an epileptic brain in the kindling model is attenuated by chronic inhibition of HDAC activity.
HDAC Inhibition Intercepts and Erases the Epileptic State.
The ultimate goal of epilepsy therapies is curing epilepsy, with complete erasal of the epileptogenic state from the brain, so that additional treatments are not needed. This goal has not been met with success so far, since there has been no drug that can truly prevent epilepsy. To our knowledge, no compounds have been identified that can erase or promote un-wiring of epileptogenic state. Unexpectedly, our studies uncovered that butyrate has the potential to reverse or erase the hyperexcitability state of epileptic animals. In fully-kindled epileptic animals, butyrate treatment and discontinuation caused seizure severity to actually decrease rather than remain at an epileptic steady-state. This dramatic outcome indicates that butyrate treatment modified the persistence of the epileptogenic state, a phenomenon called reversal or erasal of the disease. The potential mechanisms underlying such erasal or regression of epilepsy remain elusive. Epigenetic HDAC inhibition by butyrate could potentially limit the proliferation of genes involved in structural aspects of neuronal circuitry involved in seizure generation or propagation; this could reduce the severity of future epileptogenic response or facilitate "un-wiring" of hyperexcitable neuronal networks in epilepsy. Further studies are warranted to advance this novel phenomenon with other HDAC inhibitors.
HDAC Inhibition with Concurrent Antiseizure Drug Promotes Further Modification of
Epileptogenesis. Neurosteroids are powerful allosteric modulators of tonic inhibition with strong antiseizure properties (Reddy, 2010; Reddy and Estes, 2016) . A combination of both epigenetic and neurosteroid treatments could provide the "best of both worlds" with strong acute action and effective long-term antiepileptogenic management. Neurosteroids have potent seizure suppression when administered shortly before stimulation, while an epigenetic agent such as sodium butyrate offers long-term inhibition of the kindling process. In the present study, co-administration of butyrate and ganaxolone drastically slowed progress of epileptogenesis when injected daily alongside stimulations. This result persisted even after withdrawal of both drugs, with the combination treatment displaying a lasting seizure protection more potent than that of butyrate or ganaxolone alone. A combination therapy of butyrate and ganaxolone facilitated effective disease-modification as reflected by nearly complete prevention of hippocampus mossy fiber sprouting, which is a hallmark morphological index of epileptogenesis.
Therapeutic Implications of HDAC Inhibition for Curing Epilepsy. Currently, there is no known treatment that can prevent epilepsy from developing in those individuals at risk. A variety of HDAC inhibitors are currently being used in clinical trials for cancer and neurological diseases. They hold promising potential as effective epileptogenic inhibitors. This targeted strategy has many advantages, including a wide availability of clinically-approved HDAC inhibitors, a concrete strategy based on the pathogenic mechanism involved in epileptogenesis, and the potential for preventative, long-term protection rather than symptomatic treatment.
Epigenetic HDAC intervention appears a rational strategy for preventing epilepsy because it targets the primary pathway that initially triggers the numerous downstream neuronal events mediating epileptogenesis. The mechanisms underlying epigenetic regulation of epileptogenesis remain unclear, but appear to be complex and multifaceted (Walker et al., 2002; Reddy and Mohan, 2011) . Neuronal injury activates diverse signaling events, such as inflammation, apoptosis, neurogenesis and synaptic plasticity, which eventually lead to structural and functional changes in neuronal circuits (Löscher, 2002; Pitkänen et al., 2009 ). These changes are eventually manifested as abnormal network hyperexcitability and spontaneous seizures. HDACs, as upstream regulators of transcription of genes, can dynamically regulate a variety of downstream signaling pathways involved in epileptogenesis, including gene networks that govern the circuit excitability and synaptic function (Crosio et al., 2003; Dong et al., 2007; Jessberger et al., 2007; Younus and Reddy, 2017b) . The target mRNA and protein abundance assays are being performed to uncover the antiepileptogenic mechanism underlying the HDAC inhibition. Specific HDAC components may serve as valid biomarkers for epileptogenesis monitoring. One of the mechanisms of the ketogenic diet, which also has antiepileptogenic activity, is thought to be based on HDAC inhibition via β-hydroxybutyrate (Wang et al., 2017; Moreno and Mobbs, 2017) . These findings are consistent with our findings on HDAC interruption of the antiepileptogenic process. Thus, the HDAC inhibitors may hold great potential as antiepileptogenic agents for curing epilepsy. Other epigenetic mechanisms, including DNA methylation, miRNA-based transcriptional control, and bromodomain activity, may alter epileptogenesis by exerting their regulatory effects on neuronal plasticity (Younus and Reddy, 2017b) . Although such targets represent alternatives for antiepileptogenic interventions, but there are currently few approved drugs with acceptable safety profiles for experimental investigations.
In conclusion, the powerful inhibition of kindling epileptogenesis progression under both subchronic and chronic HDAC inhibition by sodium butyrate protocols suggests a critical role of the epigenetic HDAC pathway in the development and persistence of epilepsy. This was associated with reduced neuronal fiber sprouting in the hippocampus. The HDAC inhibition caused a long-lasting disease-modification and strikingly reversed the kindling epileptogenic state, which is a unique aspect of epigenetic targeting compared to traditional antiseizure treatments. These findings, therefore, envisage a novel therapy for preventing or curing epilepsy by targeting specific epigenetic HDAC pathways in the brain. In protocol #2, animals were treated with butyrate (600 mg/kg, i.p., twice daily), ganaxolone (GX, 0.5 mg/kg, s.c., 15 minutes prior to stimulation), or a combination of both drugs for 2 weeks, followed by a drug-free withdrawal period until fully kindled. In protocol #3, animals were fully kindled without any injected treatment, followed by a two week period of butyrate treatment (600 mg/kg, i.p., twice daily) and hiatus from stimulation. On the sixth week, treatment was discontinued and individual ADTs were redetermined. Animals were subsequently rekindled to full without treatment, identical in procedure to the initial kindling. Fig. 6A and 6C) were fit to the linear function Sn=Rn+A, where Sn is the mean seizure stage value for the nth stimulation, R is the rate of kindling, and A is set equal to either 0 (stimulations 1 through 14) or S14 (stimulations 14 to stage 5 kindling). The rate of kindling Rn for each of the four groups is depicted above. The control group exhibited no significant kindling difference before and after the two-week cutoff, while all 
